b2/20220119085815okyddzEyf6.png)
Aclaris Therapeutics
Manufacturing · Pennsylvania, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
701 Lee Rd Ste 103, Chesterbrook, Pennsy...Phone Number
(484) 324-7933Website
www.aclaristx.comRevenue
$8.2 MillionStock Symbol
ACRSIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Aclaris Therapeutics
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.Explore more
Aclaris Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aclaris Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Aclaris Therapeutics is spiking on competitors!
Check if Aclaris Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Aclaris Therapeutics launches new products
Aclaris Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Aclaris Therapeutics
Earning: See what the market has to say on Aclaris Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Aclaris Therapeutics has new funding data
Click to see if Aclaris Therapeutics had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Aclaris Therapeutics
Compare insights from companies similar to Aclaris Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Aclaris Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Aclaris Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Aclaris Therapeutics.
Aclaris Therapeutics financials insights
Gather financial insights about Aclaris Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Series A
$21M
2014
Series B
$21M
2015
Series C
$40M
Stock Offering
$56.5M
2016
Share Placement
$20M
2020
Debt
$11M
Aclaris Therapeutics Tech Stack
A closer look at the technologies used by Aclaris Therapeutics
Most Recent Scoops
Open Position
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Person-Based
Earnings, Business Finance, Clinical Operations, Finance
Project
Pharmaceuticals
Aclaris Therapeutics News & Media
Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)
Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical UpdateAclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On
Aclaris Therapeutics Inc. (NASDAQ:ACRS) is one of the top penny stocks to buy in investors’ stock portfolio. On May 8, Stifel reiterated a Hold rating on Aclaris Therapeutics Inc. (NASDAQ:ACRS) and increased the price target to $4 from $3. The price target hike underscores the research firm’s optimism about the company’s multi-targeting approaches and its […]Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Aclaris Therapeutics
Sign Up For FreeTo access detailed company insights
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulat... Read More
